How GLP-1 Medications Actually Work in the Body: The Incretin System Explained

A plain-language tour of the incretin system, from your gut to your pancreas to your brain, and what tirzepatide's second hormone adds.

Most people start a GLP-1 medication with a fuzzy sense that it "curbs appetite" and leave it at that. That is fine for getting started, but if you actually understand what these medicines are doing, the whole experience makes more sense: why your blood sugar improves without dropping too low, why the early fullness fades a bit after a few weeks, and why two people on similar doses can have different results. So here is the biology, in plain language, from the gut to the pancreas to the brain.

Start with a strange fact about eating

Swallow a glass of sugar water and your body releases far more insulin than it would if the exact same amount of sugar were dripped straight into a vein. That gap is called the incretin effect. In healthy people it accounts for something like 50 to 70 percent of the total insulin your body puts out after a meal. The difference is not the sugar itself; it is that food passing through your gut sends chemical messengers ahead to the pancreas, telling it that fuel is arriving.

Those messengers are the incretin hormones. There are two of them: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Your intestine makes both, but from different cells in different places. GIP comes mainly from K cells in the upper small intestine. GLP-1 comes mainly from L cells further down. Both fire off when you eat, especially carbohydrate and fat. GLP-1 is the one nearly every current weight-loss medication is built around, so it gets most of the attention here, but keep GIP in mind, because it comes back at the end.

The key trick: insulin only when glucose is high

Here is the part that explains a lot of the safety profile. GLP-1 does not force the pancreas to dump insulin on command. It amplifies the insulin response only when blood glucose is actually elevated. When your sugar is normal, GLP-1 has little to no effect on insulin release. It waits.

Under the hood, GLP-1 binds a receptor on the pancreatic beta cell and raises a signaling molecule called cyclic AMP. That primes the cell to release more insulin, but the actual trigger still has to come from glucose. So GLP-1 potentiates insulin secretion; it does not independently start it. This is why doctors describe the medication as glucose-dependent, and it is not a small detail.

Why that means a low risk of going too low

Because the insulin only shows up when glucose is high, a GLP-1 receptor agonist used on its own carries a low intrinsic risk of hypoglycemia. It tends to pull an elevated A1C back toward normal without overshooting into a dangerous low. That is a real and important distinction from older drugs like insulin and sulfonylureas, which push insulin regardless of what your sugar is doing.

Read that carefully, though. Low risk is not zero risk, and the property belongs to the GLP-1 medication acting alone. If it is layered on top of insulin or a sulfonylurea, the hypoglycemia risk goes up, and those background medications often need to be reduced by the prescriber. That is exactly why you never adjust a diabetes medication yourself. We go deeper into the numbers and the practical cautions in GLP-1 and low blood sugar.

Telling the liver to ease off

Insulin is only half of the pancreas story. The other half is glucagon, a hormone from the pancreatic alpha cells that tells your liver to release stored sugar. After a meal you do not need the liver adding more glucose, so GLP-1 suppresses glucagon, which cuts down on that hepatic glucose output and smooths the post-meal rise.

And this suppression is glucose-dependent too, which is elegant. GLP-1 quiets glucagon when sugar is normal or high, but it does not blunt the protective surge of glucagon your body relies on to rescue itself during an actual low. Your safety valve stays intact. That is one more reason the intrinsic hypoglycemia risk stays low.

Slowing the stomach down

GLP-1 also slows gastric emptying, meaning food leaves your stomach more gradually. Two things follow. The glucose from a meal trickles into the bloodstream instead of spiking, and you feel full sooner and longer because the meal is sitting there.

This is the mechanism people latch onto, and it is real, but it is worth being precise about its limits. Slowed emptying is strongest right at the start of treatment and with shorter-acting agents. With a long-acting medication like semaglutide, the body adapts over days to weeks, and much of the gastric slowing fades, a phenomenon called tachyphylaxis. Some residual slowing hangs around, but if the whole effect were just a slow stomach, the appetite benefit would wear off as the stomach re-adapts. It largely does not. Which points to where the durable action actually lives.

The part that lasts is in the brain

The biggest driver of reduced appetite and weight loss is central, not gastric. GLP-1 receptors sit in appetite-regulating regions of the brain: the arcuate nucleus of the hypothalamus and the brainstem's dorsal vagal complex. There, GLP-1 turns up the neurons that signal "satisfied" (the POMC and CART neurons) and turns down the ones that drive hunger (the NPY and AgRP neurons). This is receptor-level modulation of your satiety circuitry, not a mechanical trick that mimics a stretched stomach.

One common misconception deserves correcting: large peptide medications like semaglutide do not freely flood across the blood-brain barrier. They reach these circuits through specific gateway regions that lack the usual tight barrier, most notably the area postrema in the brainstem, along with sites near the ventricles. From there the signal spreads to the hypothalamus and brainstem. For the fuller picture of how your brain sets hunger and fullness in the first place, and why quieting that background chatter matters, see how hunger and fullness work and what food noise is.

Where tirzepatide adds a second hormone

Everything above describes a single-hormone GLP-1 medication. Tirzepatide is different. It is one molecule that activates two receptors: the GLP-1 receptor and the GIP receptor. That is why it gets called a dual agonist, or a twincretin. It is also deliberately imbalanced. It binds the GIP receptor with roughly the strength of your own natural GIP, but binds the GLP-1 receptor about five-fold more weakly than native GLP-1, with an altered signaling pattern at that receptor.

The clinical results are established. In the head-to-head SURMOUNT-5 trial (72 weeks, 751 adults with obesity and without diabetes), tirzepatide produced a mean weight reduction of 20.2 percent versus 13.7 percent for semaglutide, and more people on tirzepatide reached the higher weight-loss thresholds. Those are trial numbers, not marketing. If you are weighing the two options for yourself, semaglutide vs tirzepatide walks through the practical trade-offs.

What is genuinely not settled is why adding GIP action helps. It sounds like it should be obvious, but the field is stuck on what researchers openly call the GIP paradox: turning the GIP receptor on (tirzepatide) and turning it off (a different investigational approach) both seem to add weight loss on top of GLP-1. Leading explanations include GIP acting centrally in the brain, the imbalanced signaling profile boosting benefit while limiting gut side effects, and a kind of functional desensitization from constant stimulation. All of that is under active study. So the honest statement is that the extra hormone may add efficacy, and the mechanism behind it is still being worked out, not that GIP is definitively "burning more fat."

Why the mechanism is worth knowing

Put together, these are not five separate gimmicks. They are one coordinated shift in how your body handles food. Insulin arrives on time and only when needed, the liver stops over-supplying sugar, meals digest more gradually, and the brain's hunger signaling gets quieter. The pancreas and gut effects are textbook physiology you can count on; the brain effect is what carries the durable appetite change; and the newer dual-hormone approach adds efficacy through biology we are still mapping.

A note on sourcing, since it matters for weight-loss medications: compounded semaglutide and tirzepatide are not FDA-approved and not brand-identical to the branded products, and results vary from person to person. Ozempic and Wegovy (semaglutide) are made by Novo Nordisk; Mounjaro and Zepbound (tirzepatide) are made by Eli Lilly; this clinic is not affiliated with either company. None of this is a substitute for a conversation with a prescriber who knows your history. If you want that conversation grounded in the actual biology rather than a sales pitch, that is exactly the kind of care Dr. Anjmun Sharma, MD aims to provide.

Frequently asked questions

This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.